Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease that causes inflammation and scarring of the bile ducts. It is currently one of the leading causes of liver disease and transplantation in the developed world. PSC is a long-term condition with no cure where the bile ducts inside and outside the liver become inflamed and scarred over time, restricting the flow of bile. This results in a buildup of bile that can lead to liver damage and liver failure. Common symptoms include fatigue, itching, abdominal pain, and jaundice. The disease is treated through medications to relieve symptoms, endoscopic procedures to remove blockages, and liver transplantation in advanced cases.

The global primary sclerosing cholangitis Market is estimated to be valued at US$ 950 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The primary driver for the growth of the global primary sclerosing cholangitis market size is the increasing disease prevalence. According to various studies, PSC affects between 6 to 20 people per 100,000 in Western populations. Risk factors include genetic predisposition, inflammatory bowel disease, smoking, diabetes, autoimmune thyroid disease, and others. Familial occurrence also indicates a strong genetic component. With the above mentioned drivers and a lack of curative options, the number of cases is rising steadily worldwide. Additionally, technological advancements are leading to the development of new drug therapies and early disease detection methods, further fueling market growth over the forecast period.

SWOT Analysis

Strength: Primary sclerosing cholangitis (PSC) is an autoimmune disease that specifically affects the bile ducts of the liver. With advancements in diagnostic and treatment options, early and accurate diagnosis of PSC is now possible which can increase treatment success rates. The development of new drugs targeted at the underlying mechanisms of PSC offers hope to patients.

Weakness: There is currently no cure for PSC and existing treatment options only manage symptoms. Liver transplantation remains the only treatment that can cure PSC but transplant availability is limited and it is an invasive procedure with risks of complications and rejection. Some patients may not be eligible or a suitable candidate for transplant.

Opportunity: With a rising global prevalence rate, the primary sclerosing cholangitis market remains underpenetrated presenting major opportunities for drug developers. More research into the immunological and genetic causes of PSC can lead to novel targeted therapies and management strategies. Developing non-invasive diagnostic tools can help detect PSC earlier and increase eligible patients for curative transplant procedures.

Threats: High treatment costs associated with managing advanced PSC and liver transplantation procedures poses affordability challenges. Stringent regulatory pathways for approval of new drugs delays market availability. The unpredictable disease progression and limited standardized treatment protocols also pose clinical and commercialization risks.

Key Takeaways

The global primary sclerosing cholangitis market is expected to witness high growth over the forecast period driven by rising disease prevalence, improving diagnosis rates, and a robust pipeline of novel drugs in clinical trials. The global primary sclerosing cholangitis Market is estimated to be valued at US$ 950 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030.

Regional analysis: North America currently dominates the global PSC market due to high awareness levels, developed healthcare infrastructure, and presence of major market players. The Asia Pacific region is expected to witness fastest growth during the forecast period fueled by improving diagnostic capabilities, rising access to transplant services in major countries like China and India, and increasing research focus.

Key players: Key players operating in the primary sclerosing cholangitis market are Intercept Pharmaceuticals, Dr. Falk Pharma, Acorda Therapeutics, Gilead Sciences, HighTide Therapeutics, and Tobira Therapeutics. Intercept Pharmaceuticals' obeticholic acid is currently the only approved drug for PSC but a robust late stage pipeline is expected to introduce more treatment alternatives over the coming years.

Get More Insights On This Topic: https://www.trendingwebwire.com/primary-sclerosing-cholangitis-market-analysis-growth-forecast-outlook-2023-2030/